Canada Life’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,404
| Closed | -$127K | – | 2185 |
|
|
2023
Q3 | $127K | Sell |
11,404
-16,605
| -59% | -$267K | ﹤0.01% | 1920 |
|
|
2023
Q2 | $600K | Sell |
28,009
-1,176
| -4% | -$34.7K | ﹤0.01% | 1644 |
|
|
2023
Q1 | $1.18M | Sell |
29,185
-1,079
| -4% | -$51.5K | ﹤0.01% | 1449 |
|
|
2022
Q4 | $1.41M | Buy |
30,264
+6,691
| +28% | +$305K | ﹤0.01% | 1399 |
|
|
2022
Q3 | $1.22M | Buy |
23,573
+5,539
| +31% | +$324K | ﹤0.01% | 1402 |
|
|
2022
Q2 | $853K | Buy |
18,034
+2,211
| +14% | +$120K | ﹤0.01% | 1524 |
|
|
2022
Q1 | $1.16M | Buy |
15,823
+17
| +0.1% | +$1.11K | ﹤0.01% | 1477 |
|
|
2021
Q4 | $1.18M | Buy |
15,806
+92
| +0.6% | +$7.22K | ﹤0.01% | 1458 |
|
|
2021
Q3 | $896K | Hold |
15,714
| – | – | ﹤0.01% | 1561 |
|
|
2021
Q2 | $692K | Buy |
15,714
+33
| +0.2% | +$1.62K | ﹤0.01% | 1658 |
|
|
2021
Q1 | $769K | Sell |
15,681
-1,636
| -9% | -$81.6K | ﹤0.01% | 1608 |
|
|
2020
Q4 | $729K | Sell |
17,317
-2,437
| -12% | -$107K | ﹤0.01% | 1636 |
|
|
2020
Q3 | $904K | Sell |
19,754
-365
| -2% | -$17.7K | ﹤0.01% | 1449 |
|
|
2020
Q2 | $1.01M | Sell |
20,119
-279
| -1% | -$14.4K | ﹤0.01% | 1439 |
|
|
2020
Q1 | $1.05M | Buy |
20,398
+911
| +5% | +$48.6K | ﹤0.01% | 1268 |
|
|
2019
Q4 | $1.19M | Buy |
+19,487
| New | +$1.21M | ﹤0.01% | 1404 |
|
|
2019
Q3 | – | Sell |
-20,952
| Closed | -$1.77M | – | 1465 |
|
|
2019
Q2 | $1.77M | Buy |
20,952
+124
| +0.6% | +$11.2K | ﹤0.01% | 1248 |
|
|
2019
Q1 | $1.99M | Buy |
20,828
+719
| +4% | +$64.5K | 0.01% | 1054 |
|
|
2018
Q4 | $1.31M | Buy |
20,109
+1,657
| +9% | +$127K | ﹤0.01% | 1267 |
|
|
2018
Q3 | $1.57M | Hold |
18,452
| – | – | ﹤0.01% | 1318 |
|
|
2018
Q2 | $2.14M | Sell |
18,452
-165
| -0.9% | -$16.5K | 0.01% | 1133 |
|
|
2018
Q1 | $1.51M | Sell |
18,617
-1,218
| -6% | -$93.7K | ﹤0.01% | 1321 |
|
|
2017
Q4 | $1.16M | Sell |
19,835
-1,956
| -9% | -$97.9K | ﹤0.01% | 1474 |
|
|
2017
Q3 | $1M | Buy |
21,791
+3,006
| +16% | +$121K | ﹤0.01% | 1518 |
|
|
2017
Q2 | $676K | Hold |
18,785
| – | – | ﹤0.01% | 1633 |
|
|
2017
Q1 | $579K | Buy |
18,785
+1,600
| +9% | +$49.8K | ﹤0.01% | 1674 |
|
|
2016
Q4 | $576K | Hold |
17,185
| – | – | ﹤0.01% | 1662 |
|
|
2016
Q3 | $457K | Buy |
17,185
+1,068
| +7% | +$24.8K | ﹤0.01% | 1688 |
|
|
2016
Q2 | $355K | Buy |
+16,117
| New | +$422K | ﹤0.01% | 1727 |
|
Other funds holding ENTA
AC
FCM
KAM
Canada Life's ENTA Position: Q4 2023 in Review
Canada Life sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 11,404 shares — an estimated $127K sold.
Canada Life first reported a position in ENTA in Q2 2016 and held it in 29 quarters. The position peaked at $2.14M in Q2 2018. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.
- Canada Life reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Canada Life sold 11,404 Enanta Pharmaceuticals shares in Q4 2023, an estimated $127K.
- Canada Life first reported a position in Enanta Pharmaceuticals in Q2 2016 and held it in 29 quarters.
- Canada Life's Enanta Pharmaceuticals position peaked at $2.14M in Q2 2018.
- 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.
Based on Canada Life's 13F filing for Q4 2023, filed 13 Feb 2024.